1. Inicio
  2. Publicaciones
  3. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ruiz-Cobo, JC
  • Llaneras, J
  • Forns, X
  • Moya, AG
  • Arencibia, A
  • Diago, M
  • Garcia-Samaniego, J
  • Castellote, J
  • Llerena, S
  • Rodriguez-Seguel, E
  • Mateos, B
  • Rodriguez, M
  • Zabal, JMR
  • Fernandez, I
  • Calleja, JL
  • Morillas, RM
  • Montoliu, S
  • Andrade, RJ
  • Aranda, EB
  • Hernandez-Guerra, M
  • Mate, CJ
  • Gonzalez-Santiago, JM
  • de Cuenca, B
  • Bernal-Monterde, V
  • Delgado, M
  • Turnes, J
  • Lens, S
  • Buti, M

Grupos

Abstract

BackgroundSofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).MethodsRetrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX +/- ribavirin for 12 weeks between December 2017 and December 2022.ResultsIn total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR.ConclusionSOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is an effective rescue therapy for patients with chronic hepatitis C infection who have failed SOF/VEL and glecaprevir/pibrentasvir (GLE/PIB), achieving sustained virological response (SVR) in 89% of patients who completed treatment. There is a non-significant trend towards lower SVR rates in patients with GT3 HCV infection, cirrhosis and prior therapy with SOF/VEL.image

Datos de la publicación

ISSN/ISSNe:
0269-2813, 1365-2036

ALIMENTARY PHARMACOLOGY & THERAPEUTICS  WILEY

Tipo:
Article
Páginas:
201-211
PubMed:
38695095
Factor de Impacto:
2,850 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 9

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Cita

Compartir